m+Medelevator.RU
← Поиск публикаций
ChemMedChem · 2025

Apoptosis-Inducing Fe2+/β-Cyclodextrin Supramolecular Nano-Particulate Complex as an Anticancer Drug Platform and Cancer-Diagnostic Tool Prototype.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Sheta Sheta M, El-Sheikh Said M, Abo-Elfadl Mahmoud T, Younis Ahmed, Abd-Elzaher Mohkles M, Othman Hanibal, Strothmann Till, Fetzer Marcus N A, Boldog Istvan, Janiak Christoph

Аннотация

Beta-cyclodextrin (β-CD) metal complexes and their biomedical applications constitute an actively developing research field particularly in medicine. Herein, an iron/β-cyclodextrin (Fe(II)-β-CD) nanocomplex, synthesized at room temperature is characterized by various analytical techniques. The complex has a morphology of irregular-particles with an average of 4-10 nm, and displays a porous structure. In vitro, the particles are well-dispersible in the culture medium, which is typically an aqueous solution at pH = 7.4. The particles are stable under physiological conditions and biocompatible with living cells, making them a promising drug-delivery platform candidate. The Fe(II)-β-CD is screened for its anticancer potential against four types of malignant cell lines: liver(HepG2), breast(A549), lung(MCF7), and prostate(PC3) for the evaluation of prospective cytotoxicity properties. The results reveal that the nanocomplex show no cytotoxic effect. The dose response curves and the IC50 of the sample on each cell line are evaluated at different incubation time intervals. The apoptotic mode of cell death is the prevailing mode after 24 and 48 h. Moreover, the molecular docking for the nanocomplex as an anticancer drug against the active site of CD44 glycoprotein (PDB-ID-1poz) is investigated. Based on the obtained results, the prepared complex paves the way for similar biomarkers in cancer treatment.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты